USANA Health Sciences, Inc. (NYSE:USNA - Free Report) - Stock analysts at DA Davidson issued their Q4 2024 earnings per share estimates for shares of USANA Health Sciences in a report issued on Wednesday, October 23rd. DA Davidson analyst L. Weiser anticipates that the company will post earnings per share of $0.49 for the quarter. DA Davidson currently has a "Neutral" rating and a $35.00 price target on the stock. The consensus estimate for USANA Health Sciences' current full-year earnings is $2.50 per share.
Separately, StockNews.com cut USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a report on Wednesday, July 24th.
Read Our Latest Stock Analysis on USANA Health Sciences
USANA Health Sciences Price Performance
USANA Health Sciences stock traded down $1.00 during trading hours on Friday, hitting $36.81. 115,768 shares of the stock traded hands, compared to its average volume of 80,890. The firm's 50 day moving average price is $37.96 and its 200-day moving average price is $42.51. The stock has a market capitalization of $701.27 million, a price-to-earnings ratio of 11.54, a P/E/G ratio of 1.15 and a beta of 0.89. USANA Health Sciences has a 1 year low of $34.15 and a 1 year high of $54.81.
USANA Health Sciences (NYSE:USNA - Get Free Report) last posted its quarterly earnings results on Tuesday, October 22nd. The company reported $0.56 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.49 by $0.07. The business had revenue of $200.22 million during the quarter, compared to analysts' expectations of $208.45 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.80%. During the same quarter last year, the company posted $0.59 earnings per share.
Hedge Funds Weigh In On USANA Health Sciences
A number of institutional investors and hedge funds have recently added to or reduced their stakes in USNA. DGS Capital Management LLC raised its position in shares of USANA Health Sciences by 61.8% during the 1st quarter. DGS Capital Management LLC now owns 7,258 shares of the company's stock valued at $352,000 after buying an additional 2,773 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of USANA Health Sciences by 18.1% in the 1st quarter. BNP Paribas Financial Markets now owns 38,820 shares of the company's stock valued at $1,883,000 after purchasing an additional 5,952 shares during the last quarter. Pzena Investment Management LLC grew its holdings in shares of USANA Health Sciences by 3.1% during the 1st quarter. Pzena Investment Management LLC now owns 785,344 shares of the company's stock worth $38,089,000 after purchasing an additional 23,729 shares during the period. State Board of Administration of Florida Retirement System increased its position in shares of USANA Health Sciences by 22.7% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 8,430 shares of the company's stock worth $409,000 after purchasing an additional 1,560 shares during the last quarter. Finally, BOKF NA raised its holdings in USANA Health Sciences by 274.5% in the 1st quarter. BOKF NA now owns 2,771 shares of the company's stock valued at $133,000 after buying an additional 2,031 shares during the period. Institutional investors and hedge funds own 54.25% of the company's stock.
Insider Buying and Selling
In other USANA Health Sciences news, Director Gilbert A. Fuller sold 674 shares of the company's stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $39.69, for a total value of $26,751.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Paul A. Jones sold 6,266 shares of the firm's stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $38.38, for a total value of $240,489.08. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Gilbert A. Fuller sold 674 shares of the business's stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $39.69, for a total transaction of $26,751.06. The disclosure for this sale can be found here. Over the last three months, insiders have sold 7,940 shares of company stock valued at $311,670. Corporate insiders own 0.33% of the company's stock.
USANA Health Sciences Company Profile
(
Get Free Report)
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Featured Articles
Before you consider USANA Health Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and USANA Health Sciences wasn't on the list.
While USANA Health Sciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
